Savara Inc SVRA
Institutional shares held
162 Million
54.8K
calls
4.1K
puts
Total value of holdings
$378M
$128K
calls
$9K
puts
Market Cap
$267M
114,043,000
Shares Out.
Institutional ownership
141.77%
# of Institutions
142
We take great care to ensure that the data presented and summarized in this overview for Savara Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SVRA
View all-
Nea Management Company, LLC Timonium, MD24.5MShares$57.3 Million6.43% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA17.6MShares$41.2 Million16.36% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$28.9 Million8.25% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA11.5MShares$26.8 Million2.0% of portfolio
-
Vestal Point Capital, LP New York, NY11MShares$25.7 Million2.18% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.12MShares$19 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT8.08MShares$18.9 Million1.01% of portfolio
-
Black Rock Inc. New York, NY8.03MShares$18.8 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY7.96MShares$18.6 Million0.56% of portfolio
-
Farallon Capital Management LLC San Francisco, CA6.84MShares$16 Million0.11% of portfolio
Latest Institutional Activity in SVRA
Top Purchases
Top Sells
About SVRA
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Insider Transactions at SVRA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 20
2025
|
Richard J Hawkins |
BUY
Open market or private purchase
|
Direct |
48,225
+29.46%
|
$96,450
$2.04 P/Share
|
|
May 29
2025
|
Joseph S Mc Cracken |
BUY
Open market or private purchase
|
Direct |
10,000
+3.69%
|
$20,000
$2.08 P/Share
|
|
Mar 31
2025
|
David A Ramsay |
BUY
Open market or private purchase
|
Direct |
150,000
+5.63%
|
$300,000
$2.77 P/Share
|
|
Feb 13
2025
|
Robert Matthew Lutz Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
38,263
-9.57%
|
$76,526
$2.83 P/Share
|
|
Dec 16
2024
|
David L Lowrance Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
25,000
-6.16%
|
$75,000
$3.33 P/Share
|
|
Dec 16
2024
|
Matthew Pauls CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
54,702
-3.44%
|
$164,106
$3.31 P/Share
|
|
Dec 16
2024
|
Richard J Hawkins |
SELL
Open market or private sale
|
Direct |
8,000
-10.63%
|
$24,000
$3.32 P/Share
|
|
Dec 13
2024
|
Anne Erickson Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,263
-4.03%
|
$54,789
$3.21 P/Share
|
|
Dec 13
2024
|
David L Lowrance Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
24,350
-5.66%
|
$73,050
$3.21 P/Share
|
|
Dec 13
2024
|
David L Lowrance Chief Financial Officer |
SELL
Bona fide gift
|
Direct |
12,000
-2.71%
|
-
|
|
Dec 13
2024
|
Matthew Pauls CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
92,593
-5.5%
|
$277,779
$3.21 P/Share
|
|
Dec 12
2024
|
Anne Erickson Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+18.09%
|
-
|
|
Dec 12
2024
|
Robert Matthew Lutz Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+20.0%
|
-
|
|
Dec 12
2024
|
Braden C. Parker Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+16.0%
|
-
|
|
Dec 12
2024
|
David L Lowrance Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+18.44%
|
-
|
|
Dec 12
2024
|
Matthew Pauls CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
400,000
+19.2%
|
-
|
|
Dec 12
2024
|
Raymond Dennis Pratt Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+19.05%
|
-
|
|
Dec 12
2024
|
Nevan C Elam |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+39.02%
|
-
|
|
Dec 12
2024
|
Richard J Hawkins |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+34.71%
|
-
|
|
Dec 12
2024
|
An Van Es Johansson |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+39.02%
|
-
|
Last 12 Months Summary
Buy / Acquisition
1.41M
Shares
From
14
Insiders
| Grant, award, or other acquisition | 1.09M shares |
|---|---|
| Open market or private purchase | 328K shares |
Sell / Disposition
324K
Shares
From
9
Insiders
| Payment of exercise price or tax liability | 224K shares |
|---|---|
| Open market or private sale | 87.7K shares |
| Bona fide gift | 12K shares |